Best Peptides for Anti-Aging & Longevity: A Research-Based Guide (2026)
Published: May 8, 2026 · 16 min read · By Peter Giordano · Reviewed by Grey Peptides Editorial Board · ✓ Cited Sources
Anti-aging is the fastest-growing application area in peptide research, but the evidence base varies enormously between compounds. Growth hormone secretagogues (CJC-1295, Ipamorelin, Sermorelin) have the strongest clinical data for age-related biomarkers — they demonstrably restore youthful IGF-1 levels, improve body composition, and enhance sleep quality. Mitochondrial peptides like SS-31 (Elamipretide) have shown promise in Phase 2 clinical trials for age-related mitochondrial dysfunction. Telomere-focused peptides like Epithalon have intriguing preclinical data but minimal human evidence. And a growing category of mitochondria-derived peptides (MOTS-c, Humanin, SHLPs) represents the cutting edge of longevity research — fascinating biology, but almost entirely preclinical. This guide ranks every compound by evidence level so you can separate established science from emerging hypotheses.
Table of Contents
- How We Rank Evidence
- Tier 1: Growth Hormone Secretagogues
- Tier 2: Mitochondrial Peptides
- Tier 3: Telomere & Epigenetic Modulators
- Tier 4: NAD+ Pathway Peptides
- Tier 5: Emerging Longevity Peptides
- Cosmetic Anti-Aging Peptides
- Building an Anti-Aging Protocol
- Frequently Asked Questions
- Sources
How We Rank Evidence
Every compound below is graded on a three-tier evidence scale: High (human clinical trials with published results), Medium (limited human data, strong animal models, or Phase 1 safety data), and Low (preclinical only — animal or in vitro studies). We separate established clinical science from promising but unproven research. The ranking reflects evidence quality, not theoretical potential.
Tier 1: Growth Hormone Secretagogues
Evidence level: High · Multiple human clinical trials · FDA approval history
Growth hormone declines approximately 14% per decade after age 30 — a phenomenon called somatopause. This decline correlates with increased visceral fat, decreased lean mass, thinning skin, reduced bone density, impaired sleep quality, and slower recovery. GH secretagogues are the most clinically validated peptide approach to addressing these age-related changes.1
CJC-1295 (Mod GRF 1–29) + Ipamorelin
The current gold standard combination in anti-aging peptide therapy. CJC-1295 stimulates GH through the GHRH receptor while Ipamorelin activates the complementary ghrelin receptor, producing synergistic GH pulses 3–5x larger than either alone. Published human data demonstrates IGF-1 increases of 50–150% above baseline, improved body composition, enhanced sleep architecture, and improved skin quality over 3–6 months of use. This combination preserves natural pulsatile GH release, maintains pituitary function, and has a favorable side-effect profile compared to exogenous HGH.2
→ Full protocol details: CJC-1295 + Ipamorelin Stack Guide
Sermorelin
The original FDA-approved GHRH analog with the longest clinical safety record of any GH secretagogue — including studies of up to 2 years of continuous use without tachyphylaxis. Sermorelin has been largely replaced by CJC-1295 in clinical practice due to the latter's superior pharmacokinetics, but it remains a well-documented, lower-cost option available through compounding pharmacies.3
Tesamorelin
The only GHRH analog with an active FDA approval — for HIV-associated lipodystrophy (reduction of visceral adipose tissue). Tesamorelin has robust clinical data showing significant reductions in trunk fat and improvements in lipid profiles, making it particularly relevant for age-related visceral fat accumulation. Its FDA-approved status gives it the strongest regulatory standing of any anti-aging GH peptide, though its approved indication is narrow.4
Tier 2: Mitochondrial Peptides
Evidence level: Medium · Phase 2 clinical trials · Strong preclinical data
Mitochondrial dysfunction is increasingly recognized as a central driver of biological aging. Declining mitochondrial efficiency reduces cellular energy output, increases oxidative damage, and triggers inflammatory cascades. Peptides that target mitochondria represent a mechanistically distinct approach to aging — addressing the energy production machinery rather than hormonal decline.
SS-31 (Elamipretide)
SS-31 is a cell-permeable tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) that localizes to the inner mitochondrial membrane, where it stabilizes cardiolipin — a phospholipid essential for electron transport chain efficiency. By improving mitochondrial coupling and reducing electron leak, SS-31 enhances ATP production while decreasing reactive oxygen species (ROS) generation. It has completed Phase 2 clinical trials for Barth syndrome, heart failure, and age-related mitochondrial myopathy, with mixed but promising results. It represents the most clinically advanced mitochondria-targeted peptide in development.5
MOTS-c
MOTS-c is a mitochondria-derived peptide (MDP) encoded by mitochondrial DNA — one of a class of peptides produced by the mitochondrial genome itself. In preclinical studies, MOTS-c has demonstrated remarkable effects on metabolism: improving insulin sensitivity, enhancing exercise capacity, protecting against age-related metabolic decline, and reducing obesity in animal models. A small human study showed that circulating MOTS-c levels decline with age and correlate with metabolic health markers. However, most evidence remains preclinical. MOTS-c represents one of the most exciting areas of longevity peptide research.6
Humanin
Humanin is another mitochondria-derived peptide with cytoprotective properties. It has shown neuroprotective effects in Alzheimer's disease models, cardioprotective effects in ischemia-reperfusion models, and anti-apoptotic effects across multiple cell types. Circulating humanin levels decline with age, and low levels correlate with age-related diseases. Like MOTS-c, humanin is primarily preclinical in its evidence base for longevity applications but represents a biologically compelling target.6
Tier 3: Telomere & Epigenetic Modulators
Evidence level: Low–Medium · Limited human data · Preclinical evidence
Epithalon (Epitalon)
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) studied primarily by Russian researcher Vladimir Khavinson. Its proposed mechanism involves activation of telomerase — the enzyme that maintains telomere length, which shortens with each cell division and is considered a biomarker of biological aging. Published data (largely from Russian journals) suggests that Epithalon can activate telomerase in human somatic cells, extend telomere length in fibroblast cultures, and — most controversially — extend lifespan in animal models. The evidence is limited by small sample sizes, lack of replication by independent Western research groups, and publication primarily in non-indexed journals. Epithalon is one of the most discussed longevity peptides in biohacker communities, but its evidence should be characterized honestly as preliminary.7
Pinealon
Pinealon is a tripeptide (Glu-Asp-Arg) from the same Khavinson research program as Epithalon, developed as a potential neuroprotective and anti-aging compound targeting the pineal gland and melatonin regulation. Its evidence base is even more limited than Epithalon's, consisting primarily of cell culture studies and small Russian clinical reports.
Tier 4: NAD+ Pathway Peptides
Evidence level: Medium · Human data for NAD+ precursors · Peptide-specific data limited
NAD+ and its precursors
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme essential for cellular energy metabolism, DNA repair, and sirtuin activation. NAD+ levels decline significantly with age, and restoring youthful NAD+ levels is one of the most actively researched anti-aging strategies. While the primary approaches use small molecule precursors (NMN, NR) rather than peptides, the NAD+ pathway intersects with peptide biology through sirtuins, MOTS-c signaling, and mitochondrial function. NAD+ precursors are included here because they are frequently combined with anti-aging peptide protocols and share metabolic targets.8
Tier 5: Emerging Longevity Peptides
Evidence level: Low · Preclinical only · Theoretical frameworks
SHLPs (Small Humanin-Like Peptides)
The SHLP family (SHLP1–6) are recently discovered mitochondria-derived peptides with diverse biological activities including anti-apoptotic, metabolic, and neuroprotective effects. SHLP2 and SHLP6 have shown particular promise in preclinical aging models. This is frontier science with no human trial data yet.
GHK-Cu (Copper Peptide)
GHK-Cu is a tripeptide-copper complex that declines with age and has demonstrated broad gene-regulatory effects in transcriptomic studies — including upregulation of DNA repair genes and downregulation of inflammatory pathways. It is primarily studied topically for skin aging (where it has reasonable clinical evidence) and is being investigated systemically for broader anti-aging effects. Topical evidence: medium. Systemic longevity evidence: low.9
Thymosin Alpha-1
Thymosin Alpha-1 (Zadaxin) is an FDA-orphan-drug-designated immune-modulating peptide that enhances T-cell function. Age-related immune decline (immunosenescence) is a major contributor to increased infection susceptibility, reduced vaccine response, and chronic inflammation in the elderly. Thymosin Alpha-1 has clinical data for immune restoration in immunocompromised populations and is used in some anti-aging protocols targeting immune function.10
Cosmetic Anti-Aging Peptides
A separate category of peptides targets visible signs of skin aging — wrinkles, loss of elasticity, pigmentation — rather than systemic biological aging. These include Argireline (acetyl hexapeptide-3), Matrixyl (palmitoyl pentapeptide-4), GHK-Cu, and various collagen-stimulating peptides. These are applied topically, have reasonable evidence for improving skin appearance, but do not address underlying biological aging processes. They are covered in detail in our Cosmetic Peptide category.
Building an Anti-Aging Protocol
For readers working with a physician to design a peptide-based anti-aging protocol, the evidence supports a tiered approach.
Foundation (highest evidence): A GH secretagogue combination — typically CJC-1295 + Ipamorelin or Sermorelin — addresses the most clinically documented aspect of peptide-based anti-aging. Monitor IGF-1, fasting glucose, and HbA1c quarterly.
Addition (medium evidence): NAD+ precursors (NMN or NR) target a complementary aging pathway with reasonable human data. Some practitioners add BPC-157 for gut health and systemic cytoprotective effects, though this is supported primarily by animal data.
Experimental (low evidence): Epithalon, MOTS-c, and other longevity-specific peptides represent speculative additions. Their inclusion in a protocol should be approached with eyes open about the evidence limitations.
→ Build dosing schedules with the Protocol Builder.
→ Check for conflicts with the Interaction Checker.
Frequently Asked Questions
Do anti-aging peptides actually work?
Some compounds have strong clinical evidence for specific biomarkers of aging — GH secretagogues demonstrably raise IGF-1 and improve body composition, SS-31 has shown mitochondrial benefits in Phase 2 trials, and Epithalon has preclinical evidence for telomerase activation. However, no peptide has been proven in controlled human trials to extend lifespan. The evidence ranges from robust (GH secretagogues) to preclinical-only (most longevity-specific peptides).
What is the most researched anti-aging peptide?
GH secretagogues as a class have the most extensive human clinical data relevant to age-related decline. Among longevity-specific peptides, SS-31 (Elamipretide) has the most advanced clinical program. Epithalon has the most intriguing preclinical longevity data but very limited human evidence.
Are anti-aging peptides safe long-term?
Long-term safety data exists mainly for GH secretagogues — Sermorelin has been studied for up to 2 years. For most longevity-specific peptides, long-term human safety data is limited or nonexistent. Any long-term use should be monitored with periodic blood work under medical supervision.
Can peptides replace HGH for anti-aging?
GH secretagogues like CJC-1295 + Ipamorelin can increase your body's own GH production and offer some of the same anti-aging benefits at lower cost and with a better safety profile. They won't produce the same magnitude of GH elevation as exogenous HGH, but the trade-off is lower risk of side effects.
Related Tools & Guides
Related Articles
The most widely prescribed anti-aging peptide combination. Sermorelin: The Original GHRH Analog
FDA-approved GH secretagogue with the longest safety record. MK-677 (Ibutamoren): The Oral GH Secretagogue
The oral alternative with the most clinical trial data — and the most caveats. Best Peptides for Fat Loss
GLP-1 agonists and GH secretagogues for body composition — overlaps with anti-aging goals.
Sources
- Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocrine Reviews. 1993;14(1):20–39. doi:10.1210/edrv-14-1-20
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats. Endocrinology. 2005;146(7):3052–3058.
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006;1(4):307–308.
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359–2370. doi:10.1056/NEJMoa072375
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology. 2014;171(8):2029–2050. doi:10.1111/bph.12461
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443–454. doi:10.1016/j.cmet.2015.02.009
- Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;135(6):590–592.
- Yoshino J, Baur JA, Imai SI. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metabolism. 2018;27(3):513–528. doi:10.1016/j.cmet.2017.11.002
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International. 2015;2015:648108. doi:10.1155/2015/648108
- Tuthill C, Rios I, McBeath R. Thymalfasin: future directions. Annals of the New York Academy of Sciences. 2010;1194:130–135. doi:10.1111/j.1749-6632.2010.05488.x
Stay updated on peptide research
New articles, tool updates, and encyclopedia additions — delivered when they're ready.